Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVRL1 | P37023 | 2/20 | 0.43 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.43 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.43 |
| ▸ | ACVR1B | P36896 | 1/20 | 0.43 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.43 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17371696 | 0.87 | ALDH1A1 (0.36) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL24469661 | 0.85 | ACVRL1 (0.42) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL24469677 | 0.80 | KDM4E (0.33) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL3676870 | 0.76 | ACVRL1 (0.54) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL3203728 | 0.72 | ACVRL1 (0.38) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL29607098 | 0.72 | ACVRL1 (0.38) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL24469499 | 0.72 | ACVRL1 (0.38) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL24469506 | 0.71 | ACVRL1 (0.38) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL29606087 | 0.71 | ACVRL1 (0.38) | ACVRL1BMPR1BBMPR1AACVR1BTGFBR1 | |
| SCHEMBL3275768 | 0.69 | DPP4 (0.46) | ACVRL1ALDH1A1MEN1KMT2ADPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME LLC (US) | 2024-03-07 | — | — | US | disclosed |
| WO-2022115301-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2010-02-04 | — | — | US | disclosed |
| EP-1562612-B1 | COMBINATION PRODUCT OF INHIBITOR OF THE SRC FAMILY OF NON-RECEPTOR TYROSINE KINASES AND GEMCITABINE FOR USE IN THE TREATMENT OR PROPHLAXIX OF PANCREATIC CANCER | ASTRAZENECA AB (SE) | 2010-01-27 | — | — | EP | disclosed |
| US-7462623-B2 | Quinazoline derivatives as Src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2008-12-09 | — | — | US | disclosed |
| EP-1562955-B1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2008-02-27 | — | — | EP | disclosed |
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | ASTRAZENECA AB (SE) | 2006-10-05 | — | — | US | disclosed |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | US | disclosed |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | ASTRAZENECA AB (SE) | 2006-06-08 | — | — | US | disclosed |
| EP-1620104-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | Astrazeneca AB (SE) | 2006-02-01 | — | — | EP | disclosed |
| EP-1562955-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | Astrazeneca AB (SE) | 2005-08-17 | — | — | EP | disclosed |
| WO-2004098604-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | ASTRAZENECA AB (SE) | 2004-11-18 | — | — | WO | disclosed |
| WO-2004087120-A2 | USE OF QUINAZOLINE DERIVATIVES WITH SRC KINASE INHIBITORY ACTIVITY FOR THE TREATMENT OF HYPERTENSION | ASTRAZENECA AB (SE) | 2004-10-14 | — | — | WO | disclosed |
| WO-2004069249-A1 | 3-CYANO-QUINOLINE DERIVATIVES AS NON-RECEPTOR TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-08-19 | — | — | WO | disclosed |
| WO-2004041829-A1 | QUINAZOLINE DERIVATIVES AS SRC TYROSINE KINASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-05-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223815-A1 | Therapeutic agents comprising an anti-angiogenic agent in combination with an src-inhibitor and their therapeutic use | SRC, TEK, FLT4 | ACVRL1 1251/4885BMPR1B 1323/4885BMPR1A 997/4885 |
| US-20060142297-A1 | Combination product of inhibitor of the src family of non-recetpor tyrosine kinases and gemcitabine | SRC, PTPN4, PTPN1 | ACVRL1 4211/4885BMPR1B 3903/4885BMPR1A 3497/4885 |
| US-20100029673-A1 | THERAPEUTIC AGENTS COMPRISING AN ANTI-ANGIOGENIC AGENT IN COMBINATION WITH AN SRC-INHIBITOR AND THEIR THERAPEUTIC USE | SRC, CHUK, CTTN | ACVRL1 2606/4885BMPR1B 3632/4885BMPR1A 3563/4885 |
| US-20240076291-A1 | MODIFIED ISOINDOLINONES AS GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, ASAH2 | ACVRL1 2878/4885BMPR1B 4562/4885BMPR1A 4678/4885 |
| US-20060122199-A1 | Quinazoline derivatives as src tyrosine kinase inhibitors | SRC, ABL1, ERBB2 | ACVRL1 3551/4885BMPR1B 4228/4885BMPR1A 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.